To further analyze the potential of TLR-inhibiting strategies in overexpressing immune cells and nonimmune cells, with a focus on tumor cells, we developed intrabodies against the most interesting candidates, TLR2 and TLR9, and tested their inhibitory effects first in proof-of-principle experiments in inflammatory diseases [24,25]. Here, TLR9 is linked to neoplasm.